Filing Analysis
📢 Regulation FD Disclosure
Filed May 13, 2026
⚪ LOW
Spero Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
🚩 Red Flags
- Concentration of executive authority: Esther Rajavelu holds three major C-suite roles (CEO, CFO, and CBO) simultaneously, which may present governance risks.
📋 Key Facts
- Reported Q1 2026 financial results on May 13, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Esther Rajavelu is currently serving as the Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
📢 Regulation FD Disclosure
Filed Mar 26, 2026
⚪ LOW
Spero Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a standard periodic update on the company's operations and financial condition.
🚩 Red Flags
- Concentration of executive authority: Esther Rajavelu holds the positions of CEO, CFO, and CBO simultaneously, which may indicate lean staffing or potential governance risks in a public company.
📋 Key Facts
- Reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
- The announcement was made via a press release dated March 26, 2026, furnished as Exhibit 99.1.
- Esther Rajavelu is currently serving in the combined roles of Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.